Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2023-03-17 Sale | 2023-03-20 4:36 pm | Talaris Therapeutics Inc. | TALS | Ildstad Suzanne Director | 10,436 | $2.0643 | $21,543 | 5,562,534 (Indirect Direct) | View |
| 2023-03-03 Sale | 2023-03-07 4:58 pm | Talaris Therapeutics Inc. | TALS | Ildstad Suzanne Director | 6,806 | $2.0559 | $13,992 | 5,572,970 (Indirect Direct) | View |
| 2023-03-01 Sale | 2023-03-02 5:26 pm | Talaris Therapeutics Inc. | TALS | Ildstad Suzanne Director | 29 | $2.05 | $59 | 5,579,776 (Indirect Direct) | View |
| 2023-02-21 Sale | 2023-02-23 5:01 pm | Talaris Therapeutics Inc. | TALS | Ildstad Suzanne Director | 3,500 | $2.0529 | $7,185 | 5,579,805 (Indirect Direct) | View |
| 2023-02-16 Sale | 2023-02-21 11:16 am | Talaris Therapeutics Inc. | TALS | Ildstad Suzanne Director | 6,551 | $2.0525 | $13,446 | 5,583,305 (Indirect Direct) | View |
| 2022-07-19 Purchase(A) | 2022-09-13 4:27 pm | Talaris Therapeutics Inc. | TALS | Nader Francois Director | 138,500 | $3.6103 | $500,020 | 1,160,796 (Indirect Direct) | View |
| 2022-08-22 Sale | 2022-08-23 7:43 pm | Talaris Therapeutics Inc. | TALS | Ildstad Suzanne Chief Scientific Officer | 525,000 | $2.8 | $1,470,000 | 5,589,856 (Indirect Direct) | View |
| 2022-07-29 Purchase | 2022-08-02 5:02 pm | Talaris Therapeutics Inc. | TALS | Requadt Scott Chief Executive Officer | 39,382 | $4.25 | $167,374 | 958,446 (Indirect Direct) | View |
| 2022-07-26 Purchase | 2022-07-28 7:52 pm | Talaris Therapeutics Inc. | TALS | Requadt Scott Chief Executive Officer | 8,618 | $4.2436 | $36,571 | 919,064 (Indirect Direct) | View |
| 2022-07-22 Purchase | 2022-07-26 7:38 pm | Talaris Therapeutics Inc. | TALS | Requadt Scott Chief Executive Officer | 9,444 | $3.7497 | $35,412 | 910,446 (Indirect Direct) | View |
| 2022-07-19 Purchase | 2022-07-25 7:35 pm | Talaris Therapeutics Inc. | TALS | Nader Francois Director | 138,500 | $3.6103 | $500,020 | 1,160,796 (Indirect Direct) | View |
| 2021-05-11 Purchase | 2021-05-14 06:15 am | Talaris Therapeutics Inc. | TALS | Clarus Lifesciences III L.P. Clarus Ventures III GP L.P. Blackstone Clarus III L.L.C. Blackstone Clarus GP L.P. Blackstone Holdings I L.P. Blackstone Holdings II L.P. Blackstone Holdings I/II GP L.L.C. Blackstone Group Inc Blackstone Group Management L.L.C. SCHWARZMAN STEPHEN A 10% Owner | 30,000 | $17 | $510,000 | 160,044 (Indirect) | View |
| 2021-05-11 Purchase | 2021-05-13 9:59 pm | Talaris Therapeutics Inc. | TALS | Clarus Defined Exit I L.P. Clarus DE II L.P. Clarus IV-A L.P. Clarus IV-B L.P. Clarus IV-C L.P. Clarus IV-D L.P. Clarus Ventures DE GP L.P. Clarus IV GP L.P. Blackstone Clarus DE L.L.C. Blackstone Clarus GP L.L.C. 10% Owner | 30,000 | $17 | $510,000 | 160,044 (Indirect) | View |
| 2021-05-11 Purchase | 2021-05-11 8:29 pm | Talaris Therapeutics Inc. | TALS | Agarwala Sandip Director 10% Owner | 235,000 | $17 | $3,995,000 | 3,220,775 (Indirect) | View |
| 2021-05-11 Purchase | 2021-05-11 8:29 pm | Talaris Therapeutics Inc. | TALS | Longitude Capital Partners III LLC Longitude Venture Partners III L.P. ENRIGHT PATRICK G Tammenoms Bakker Juliet 10% Owner | 235,000 | $17 | $3,995,000 | 3,220,775 (Indirect) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2023-02-01 Option Award | 2023-02-03 5:02 pm | N/A 2033-02-01 | Talaris Therapeutics Inc. | TALS | Zdanowski Michael Chief Technology Officer | 300,000 | $0 | 300,000 (Direct) | View |
| 2022-12-30 Option Award | 2023-02-03 5:01 pm | N/A N/A | Talaris Therapeutics Inc. | TALS | Requadt Scott Chief Executive Officer | 4 | $0.867 | 1,679,959 (Direct) | View |
| 2023-02-01 Option Award | 2023-02-03 5:01 pm | N/A 2033-02-01 | Talaris Therapeutics Inc. | TALS | Requadt Scott Chief Executive Officer | 640,000 | $0 | 1,679,959 (Direct) | View |
| 2023-02-01 Option Award | 2023-02-03 4:59 pm | N/A 2033-02-01 | Talaris Therapeutics Inc. | TALS | Krieger Nancy Chief Medical Officer | 240,000 | $0 | 240,000 (Direct) | View |
| 2023-02-01 Option Award | 2023-02-03 4:57 pm | N/A 2033-02-01 | Talaris Therapeutics Inc. | TALS | Fenton Mary Kay Chief Financial Officer | 300,000 | $0 | 300,000 (Direct) | View |
| 2022-09-10 Option Award | 2022-09-13 4:31 pm | N/A N/A | Talaris Therapeutics Inc. | TALS | Zdanowski Michael Chief Technology Officer | 120,000 | $0 | 121,470 (Direct) | View |
| 2022-09-10 Option Award | 2022-09-13 4:30 pm | N/A N/A | Talaris Therapeutics Inc. | TALS | Krieger Nancy Chief Medical Officer | 80,000 | $0 | 330,233 (Direct) | View |
| 2022-09-10 Option Award | 2022-09-13 4:30 pm | N/A N/A | Talaris Therapeutics Inc. | TALS | Requadt Scott Chief Executive Officer | 80,000 | $0 | 1,039,955 (Direct) | View |
| 2022-09-10 Option Award | 2022-09-13 4:29 pm | N/A N/A | Talaris Therapeutics Inc. | TALS | Fenton Mary Kay Chief Financial Officer | 80,000 | $0 | 81,000 (Direct) | View |
| 2022-07-21 Other(A) | 2022-09-13 4:27 pm | N/A N/A | Talaris Therapeutics Inc. | TALS | Nader Francois Director | 386,932 | $0 | 1,160,796 (Indirect) | View |
| 2022-07-21 Other | 2022-07-25 7:35 pm | N/A N/A | Talaris Therapeutics Inc. | TALS | Nader Francois Director | 386,932 | $0 | 1,160,796 (Indirect) | View |
| 2022-06-09 Option Award | 2022-06-13 6:20 pm | N/A 2032-06-08 | Talaris Therapeutics Inc. | TALS | MCDADE MARK Director | 14,501 | $0 | 14,501 (Direct) | View |
| 2022-06-09 Option Award | 2022-06-13 6:16 pm | N/A 2032-06-08 | Talaris Therapeutics Inc. | TALS | Shah Gaurav Director | 14,501 | $0 | 14,501 (Direct) | View |
| 2022-06-09 Option Award | 2022-06-13 6:16 pm | N/A 2032-06-08 | Talaris Therapeutics Inc. | TALS | Smith Karen L. Director | 14,501 | $0 | 14,501 (Direct) | View |
| 2022-06-09 Option Award | 2022-06-13 6:15 pm | N/A 2032-06-08 | Talaris Therapeutics Inc. | TALS | MACKAY GEOFFREY Director | 14,501 | $0 | 14,501 (Direct) | View |
| 2022-06-09 Option Award | 2022-06-13 6:14 pm | N/A 2032-06-08 | Talaris Therapeutics Inc. | TALS | Nader Francois Director | 14,501 | $0 | 14,501 (Direct) | View |
| 2022-06-09 Option Award | 2022-06-13 6:13 pm | N/A 2032-06-08 | Talaris Therapeutics Inc. | TALS | Agarwala Sandip Director 10% Owner | 14,501 | $0 | 14,501 (Direct) | View |
| 2022-06-09 Option Award | 2022-06-13 6:11 pm | N/A 2032-06-08 | Talaris Therapeutics Inc. | TALS | Srivastava Sapna Director | 14,501 | $0 | 14,501 (Direct) | View |
| 2022-05-16 Option Award | 2022-05-17 6:15 pm | N/A 2032-05-15 | Talaris Therapeutics Inc. | TALS | Smith Karen L. Director | 29,002 | $0 | 29,002 (Direct) | View |
| 2021-11-17 Gift | 2022-02-02 6:04 pm | N/A N/A | Talaris Therapeutics Inc. | TALS | Ildstad Suzanne Chief Scientific Officer | 1,200,000 | $0 | 6,264,856 (Direct) | View |
| 2022-02-01 Option Award | 2022-02-02 6:04 pm | N/A 2032-01-31 | Talaris Therapeutics Inc. | TALS | Ildstad Suzanne Chief Scientific Officer | 150,000 | $0 | 6,264,856 (Direct) | View |
| 2022-02-01 Option Award | 2022-02-02 6:02 pm | N/A 2032-01-31 | Talaris Therapeutics Inc. | TALS | Krieger Nancy Chief Medical Officer | 190,000 | $0 | 190,000 (Direct) | View |
| 2021-12-31 Option Award | 2022-02-02 6:01 pm | N/A N/A | Talaris Therapeutics Inc. | TALS | Requadt Scott Chief Executive Officer | 1,470 | $13 | 1,401,002 (Direct) | View |
| 2022-02-01 Option Award | 2022-02-02 6:01 pm | N/A 2032-01-31 | Talaris Therapeutics Inc. | TALS | Requadt Scott Chief Executive Officer | 500,000 | $0 | 1,401,002 (Direct) | View |
| 2021-12-31 Option Award | 2022-02-02 6:00 pm | N/A N/A | Talaris Therapeutics Inc. | TALS | Fenton Mary Kay Chief Financial Officer | 1,000 | $13 | 201,000 (Direct) | View |
| 2022-02-01 Option Award | 2022-02-02 6:00 pm | N/A 2032-01-31 | Talaris Therapeutics Inc. | TALS | Fenton Mary Kay Chief Financial Officer | 200,000 | $0 | 201,000 (Direct) | View |
| 2021-12-31 Option Award | 2022-02-02 6:00 pm | N/A N/A | Talaris Therapeutics Inc. | TALS | Zdanowski Michael Chief Technology Officer | 1,470 | $13 | 201,470 (Direct) | View |
| 2022-02-01 Option Award | 2022-02-02 6:00 pm | N/A 2032-01-31 | Talaris Therapeutics Inc. | TALS | Zdanowski Michael Chief Technology Officer | 200,000 | $0 | 201,470 (Direct) | View |
| 2021-12-15 Gift | 2021-12-16 4:05 pm | N/A N/A | Talaris Therapeutics Inc. | TALS | Nader Francois Director | 59,520 | $0 | 336,167 (Indirect) | View |
| 2021-05-11 Conversion | 2021-05-14 06:15 am | N/A N/A | Talaris Therapeutics Inc. | TALS | Clarus Lifesciences III L.P. Clarus Ventures III GP L.P. Blackstone Clarus III L.L.C. Blackstone Clarus GP L.P. Blackstone Holdings I L.P. Blackstone Holdings II L.P. Blackstone Holdings I/II GP L.L.C. Blackstone Group Inc Blackstone Group Management L.L.C. SCHWARZMAN STEPHEN A 10% Owner | 51,176,706 | $0 | 160,044 (Indirect) | View |
| 2021-05-11 Conversion | 2021-05-13 9:59 pm | N/A N/A | Talaris Therapeutics Inc. | TALS | Clarus Defined Exit I L.P. Clarus DE II L.P. Clarus IV-A L.P. Clarus IV-B L.P. Clarus IV-C L.P. Clarus IV-D L.P. Clarus Ventures DE GP L.P. Clarus IV GP L.P. Blackstone Clarus DE L.L.C. Blackstone Clarus GP L.L.C. 10% Owner | 51,176,706 | $0 | 160,044 (Indirect) | View |
| 2021-05-11 Conversion | 2021-05-11 8:29 pm | N/A N/A | Talaris Therapeutics Inc. | TALS | Agarwala Sandip Director 10% Owner | 5,971,550 | $0 | 3,220,775 (Indirect) | View |
| 2021-05-11 Conversion | 2021-05-11 8:29 pm | N/A N/A | Talaris Therapeutics Inc. | TALS | Longitude Capital Partners III LLC Longitude Venture Partners III L.P. ENRIGHT PATRICK G Tammenoms Bakker Juliet 10% Owner | 5,971,550 | $0 | 3,220,775 (Indirect) | View |
Ownership | 2021-05-06 9:34 pm | N/A N/A | Talaris Therapeutics Inc. | TALS | Clarus Lifesciences III L.P. Clarus Ventures III GP L.P. Blackstone Clarus III L.L.C. Blackstone Clarus GP L.P. Blackstone Holdings I L.P. Blackstone Holdings II L.P. Blackstone Holdings I/II GP L.L.C. Blackstone Group Inc Blackstone Group Management L.L.C. SCHWARZMAN STEPHEN A 10% Owner | 0 | $0 | 8,059,315 (Indirect) | View |
Ownership | 2021-05-06 9:31 pm | N/A N/A | Talaris Therapeutics Inc. | TALS | Agarwala Sandip Director 10% Owner | 0 | $0 | 2,985,775 (Indirect) | View |